Dr. Gregory Berk
Equibles does not estimate personal net worth.
Get an email with a short summary when GT Biopharma, Inc. publishes a filing, an earnings call transcript or a press release.
Get GTBP alertsAbout Dr. Gregory Berk
Dr. Gregory Berk is recorded as CEO at GT Biopharma, Inc. (GTBP). GT Biopharma, Inc. reported in an 8-K filed December 13, 2022 that Dr. Gregory Berk was terminated as President of Research & Development and Chief Medical Officer, effective December 8, 2022. The proxy statement of GT Biopharma, Inc. reports total compensation of $1,424,519 for Dr. Gregory Berk in fiscal 2021, including a base salary of $311,841. Disclosed compensation is on record for 2 fiscal years. GT Biopharma, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at GT Biopharma, Inc. includes Anthony Cataldo (CEO), Michael Breen (CEO and Board Member), Bruce Wendel (Chairman) and 7 others.
“Effective December 8, 2022, Dr. Gregory Berk, President of Research & Development and Chief Medical Officer, is no longer employed by the Registrant.”
Affiliation history
-
Current
-
GT Biopharma, Inc. (GTBP)
SEC 8-K
2021-04-23–2022-12-08
Company network
Leadership on record at GT Biopharma, Inc.
- Anthony Cataldo CEO
- Michael Breen CEO, Board Member
- Bruce Wendel Chairman
- Alan L. Urban CFO, Board Member
- Alan Urban CFO
- Dr. Gavin Choy CFO
- Michael Handelman CFO
- Andrew Ritter Board Member
- Charles J. Casamento Board Member
- David C. Mun-Gavin Board Member
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2021 | GT Biopharma, Inc. (GTBP) | Former Interim Chief Executive Officer, President of Research & Development and Chief Medical Officer | $311,841 | $1,424,519 |
| 2020 | GT Biopharma, Inc. (GTBP) | Former Interim Chief Executive Officer, President of Research & Development and Chief Medical Officer | — | — |